Amedisys Inc versus American Renal Associates Holdings Inc Head to Head Compare

Date Published:

This is a head to head compare of Amedisys Inc (NASDAQ:AMED) and American Renal Associates Holdings Inc (NYSE:ARA) . We will compare the two companies on revenue growth, earnings, revenue per employee, operating margins, free cash flow and valuation. The head to head compare assigns 100 points in total.

Before we dive into the analysis, we will look at the stock returns for each company over the last three months, six months and the last year. The stock returns do not impact the head to head compare scores which are focused on the fundamentals of each company, but ultimately stock returns are are still a critical piece to a full analysis and compare.

Stock Returns
Symbol 3-Months 6-Months One-Year Fundamentals
AMED +13.7% +20.1% +4.2%
ARA -12.0% -5.0% -34.9%

These companies have the same star rating so the head-to-head compare will rely on a deep dive into specific metric comparisons. The CML Star Rating is an objective, quantifiable measure of a company's operating and financial condition. The rating is computed by measuring numerous elements of the company's current financial data and their associated changes over time.

Now, let's dive into the two companies to compare them.

➤ Income Statement
First we turn to the income statement and compare revenue, earnings and revenue per employee for both companies. We note that simple revenue comparisons do not impact the rating.

Amedisys Inc has larger revenue in the last year than American Renal Associates Holdings Inc. Raw revenue comps do not affect the head to head rating.

Both AMED and ARA show positive earnings over the last year with the edge to AMED.

Net Income

ARA generates massively larger revenue per employee ($162,000) than AMED ($79,000).

Revenue per Employee
($ Millions)

➤ Margins
Next we create some derived metrics to compare the the amount of revenue earned per dollar of expense and the amount of free cash flow earned per dollar of revenue. Margins are one of the fairest ways to compare companies since they remove some of the bias of large versus small numbers.

American Renal Associates Holdings Inc generates $1.22 in revenue for every $1 of expense, notably higher than Amedisys Inc's $1.04.

Revenue per Dollar of Expense

ARA generates $0.15 in levered free cash flow for every $1 of revenue, massively higher than AMED's $0.03.

Free Cash Flow
per Dollar of Revenue

➤ Growth
Finally we compare the financial metrics related to growth: revenue growth rates and price to sales.

Both companies are growing revenue. American Renal Associates Holdings Inc is growing revenue faster than Amedisys Inc but not by a notable amount.

Revenue Growth

For every $1 in revenue, the stock market prices in $1.16 in market cap for AMED and $0.97 in market cap for ARA.

Price to Sales

American Renal Associates Holdings Inc (NYSE:ARA)
Amedisys Inc (NASDAQ:AMED) : 56 to 44